Perceptive Advisors’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-11,203,881
| Closed | -$37.3M | – | 139 |
|
|
2019
Q4 | $37.3M | Hold |
11,203,881
| – | – | 0.74% | 35 |
|
|
2019
Q3 | $34.1M | Buy |
11,203,881
+6,542,057
| +140% | +$18.4M | 0.92% | 30 |
|
|
2019
Q2 | $11.1M | Hold |
4,661,824
| – | – | 0.25% | 61 |
|
|
2019
Q1 | $17.5M | Hold |
4,661,824
| – | – | 0.49% | 42 |
|
|
2018
Q4 | $15.8M | Buy |
4,661,824
+1,554,400
| +50% | +$6.76M | 0.6% | 41 |
|
|
2018
Q3 | $17.8M | Buy |
3,107,424
+1,990,100
| +178% | +$11.4M | 0.48% | 44 |
|
|
2018
Q2 | $5.6M | Hold |
1,117,324
| – | – | 0.15% | 72 |
|
|
2018
Q1 | $5.73M | Hold |
1,117,324
| – | – | 0.16% | 79 |
|
|
2017
Q4 | $6.71M | Hold |
1,117,324
| – | – | 0.22% | 68 |
|
|
2017
Q3 | $6.2M | Hold |
1,117,324
| – | – | 0.24% | 63 |
|
|
2017
Q2 | $5.18M | Sell |
1,117,324
-205,670
| -16% | -$918K | 0.26% | 66 |
|
|
2017
Q1 | $6.55M | Hold |
1,322,994
| – | – | 0.37% | 53 |
|
|
2016
Q4 | $14.7M | Sell |
1,322,994
-50,290
| -4% | -$473K | 1.04% | 24 |
|
|
2016
Q3 | $12.7M | Buy |
1,373,284
+578,284
| +73% | +$4.83M | 0.82% | 30 |
|
|
2016
Q2 | $5.05M | Buy |
+795,000
| New | +$5.28M | 0.35% | 57 |
|
Perceptive Advisors's FOMX Position: Q1 2020 in Review
Perceptive Advisors sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q1 2020, closing a stake of 11,203,881 shares — an estimated $37.3M sold.
Perceptive Advisors first reported a position in FOMX in Q2 2016 and held it in 15 quarters. The position peaked at $37.3M in Q4 2019. 3 funds tracked by Wall St. Rank hold FOMX as of Q1 2020.
- Perceptive Advisors reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q1 2020 after selling out during the quarter.
- Perceptive Advisors sold 11,203,881 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q1 2020, an estimated $37.3M.
- Perceptive Advisors first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q2 2016 and held it in 15 quarters.
- Perceptive Advisors's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $37.3M in Q4 2019.
- 3 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q1 2020.
Based on Perceptive Advisors's 13F filing for Q1 2020, filed 15 May 2020.